Faricimab

Unassigned

New Medicines

Diabetic macular oedema in treatment naive patients

Information

New molecular entity
Genentech
Genentech

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Simultaneously binds to and inactivates vascular endothelial growth factor A (VEGF-A) and Angiopoietin-2 (Ang-2)
There are almost 3.6 million people who have been diagnosed with diabetes in the UK. One study has found that macular oedema is present in 9% of the population with diabetes. [1,2]
Diabetic macular oedema in treatment naive patients
Intravitreal